Overview

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Status:
RECRUITING
Trial end date:
2028-12-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta-cel infusion following a cyclophosphamide and fludarabine lymphodepletion regimen.
Phase:
PHASE2
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Cyclophosphamide
fludarabine
Neoadjuvant Therapy